Dow Down0.92% Nasdaq Down0.83%

Synthetic Biologics Inc. (SYN)

-NYSE MKT
1.73 Up 0.07(4.22%) Oct 22, 4:01PM EDT
ProfileGet Profile for:
Synthetic Biologics Inc.
155 Gibbs Street
Suite 412
Rockville, MD 20850
United States - Map
Phone: 734-332-7800
Fax: 734-332-7878
Website: http://www.syntheticbiologics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:9

Business Summary 

Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company’s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Synthetic Biologics Inc.

Key Executives 
 PayExercised
Mr. Jeffrey L. Riley MBA, 51
Chief Exec. Officer, Pres and Director
364.00K0.00
Mr. C. Evan Ballantyne , 54
Chief Financial Officer, Principal Accounting Officer, Corp. Sec. and Treasurer
314.00K0.00
Ms. Kris M. Maly ,
VP of Corp. Communication
N/AN/A
Dr. John Monahan Ph.D., 68
Exec. VP of R&D
N/AN/A
Dr. Michael Kaleko M.D., Ph.D.,
Sr. VP of R&D
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders